El Instituto Nacional de Cancerología es una institución de atención médica, enseñanza e investigación científica perteneciente a la Secretaría de Salud de México cuya especialidad es el tratamiento de distintos tipos de cáncer.

During the past decade, Instituto Nacional de Cancerología conducted 56 clinical trials. In the 10-year time frame, 56 clinical trials started and 24 clinical trials were completed, i.e. on average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 17 clinical trials were completed. i.e. 73.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto Nacional de Cancerología" #1 sponsor was "Hoffmann-La Roche" with 20 trials, followed by "National Institute of Cancerología" with 18 trials sponsored, "Instituto Nacional de Cancerologia de Mexico" with 14 trials sponsored, "Pfizer" with 7 trials sponsored and "Janssen Research & Development, LLC" with 7 trials sponsored. Other sponsors include 26 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto Nacional de Cancerología" #1 collaborator was "National Cancer Institute (NCI)" with 6 trials as a collaborator, "Instituto Nacional de Cancerologia de Mexico" with 5 trials as a collaborator, "Instituto Nacional de Enfermedades Respiratorias" with 5 trials as a collaborator, "National Council of Science and Technology, Mexico" with 4 trials as a collaborator and "Psicofarma S.A. de C.V." with 4 trials as a collaborator. Other collaborators include 71 different institutions and companies that were collaborators in the rest 71 trials.

According to Clinical.Site data, the most researched conditions in "Instituto Nacional de Cancerología" are "Breast Cancer" (12 trials), "Lung Cancer" (6 trials), "Carcinoma, Non-Small-Cell Lung" (5 trials), "Cervical Cancer" (5 trials) and "Gastric Cancer" (3 trials). Many other conditions were trialed in "Instituto Nacional de Cancerología" in a lesser frequency.

Most popular intervention types in "Instituto Nacional de Cancerología" are "Drug" (66 trials), "Other" (21 trials), "Procedure" (10 trials), "Radiation" (5 trials) and "Biological" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "Carboplatin" (8 trials), "Paclitaxel" (8 trials), "Atezolizumab" (7 trials) and "Pertuzumab" (7 trials). Other intervention names were less common.

The vast majority of trials in "Instituto Nacional de Cancerología" are 72 trials for "All" genders, 19 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Instituto Nacional de Cancerología". undefined are not yet recruiting, 14 are recruiting, 20 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 30 completed trials in Instituto Nacional de Cancerología, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto Nacional de Cancerología, 2 "Phase 1" clinical trials were conducted, 25 "Phase 2" clinical trials and 40 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 11 trials that are defined as “Not Applicable".

Instituto Nacional de Cancerología has several departments that took part in Clinical trials: "Hospital General de México; Unidad de Oncologia" - 4 trials, "Hospital General de Mexico Servicio EndocrinologiaJefe Del Servicio" - 2 trials, "Hospital General De Mexico; Rheumatology" - 2 trials